| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
dronedarone hydrochloride
|
141625-93-6 |
决奈达隆盐酸盐
|
决奈达隆盐酸盐;N-[2-丁基-3-[4-[3-(二丁氨基)丙氧基] 苯基]-5-苯并呋喃基]-甲烷磺酰胺;CS-132;决奈达隆中间体1;盐酸决奈达隆N-[2-丁基-3-[4-[3-(二丁基氨基)丙氧基]苯甲酰基]-5-苯并呋喃基]甲磺酰胺盐酸盐;决奈达隆2;决奈达隆盐酸盐;N-[2-丁基-3-[4-[3-(二丁基氨基)丙氧基]苯甲酰基]-6-苯并呋喃基]甲磺酰胺盐酸盐
|
C31H44N2O5S.ClH |
593.224 | |
|
Tigecycline
|
220620-09-7 |
替加环素
|
替吉环素;替加环素杂质I;(4S,4aS,5aR,12aS)-4,7-双(二甲氨基)-9-[(叔丁基氨基)乙酰胺基]-3,10,12,12a-四羟基-1,11-二氧代-1,4,4a,5,5a,6,11,12a-八氢并四苯-3-甲酰胺;替加环素(TIGECYCLINE);替加环素(标准品);替吉环素;替加环素
|
C29H39N5O8 |
585.65 | 685-736-6 |
|
Entecavir hydrate
|
209216-23-9 |
恩替卡韦一水合物
|
CS-130;2-氨基-9-[(1S,3R,4S)-4-羟基-3-羟甲基-2-亚甲戊基]-1,9-氢-6-H-嘌呤-6-酮水合物;ETV;BARACLUDE;SQ 34676;BMS 200475;SQ34676;BMS200475;SQ-34676;BMS-200475;2-氨基-9-[(1S,9-氢-6-H-嘌呤-6-酮一水合物;9-(4-羟基-3-羟甲基-2-亚甲基环戊-1-基)鸟嘌呤水合物;恩替卡韦一水合物;恩替卡韦一水物;恩替卡韦;9-(4-羟基-3-羟甲基-2-亚甲基环戊-1-基)鸟嘌呤水合物
|
C12H15N5O3.H2O |
295.3 | 606-668-5 |
|
Camostat mesylate
|
59721-29-8 |
甲磺酸卡莫司他
|
甲磺酸卡莫司他;2-(二甲基氨基)-2-氧代乙基 4-(4-胍基苯甲酰氧基)苯乙酸酯甲磺酸盐;CAMOSTAT (FOY305;FOY-S980);甲磺酸卡莫他特;FOY-S981)甲磺酸盐;卡莫他特甲磺酸盐
|
C21H26N4O8S |
494.52 | 694-565-6 |
|
Raloxifene hydrochloride
|
82640-04-8 |
盐酸雷洛昔芬
|
盐酸雷洛昔芬;盐酸雷洛西芬;CS-127;[6-羟基-2-(4-羟苯基)苯并[b]噻酚-3-基]-[4-[2-(1-哌啶基)乙氧基]-苯基]-甲酮盐酸盐;雷洛芬;雷洛西芬中间体;酸雷洛昔芬;盐酸雷洛昔芬 10G
|
C28H27NO4S.HCl |
510.04422 | 639-789-7 |
|
Rivastigmine tartrate
|
129101-54-8 |
酒石酸卡巴拉汀
|
酒石酸利斯的明(酒石酸利伐斯的明);酒石酸利伐斯的明;卡巴拉汀酒石酸盐;重酒石酸卡巴拉汀;L-酒石酸卡巴拉汀;酒石酸卡巴拉汀,乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂;酒石酸卡巴拉汀;酒石酸利伐斯的明;酒石酸卡巴拉汀129101-54-9
|
C14H22N2O2·C4H6O6 |
400.43 | 603-318-3 |
|
SC-26196
|
218136-59-5 |
ALPHA,ALPHA-二苯基-4-[(3-吡啶亚甲基)氨基]-1-吡嗪戊腈
|
SC 26196 - PF 06341724;SC 26196;α,α-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile;alpha,alpha-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile;α,α-Diphenyl-4-[(3-pyridinylMethylene)aMino]-1-piperazine;2,2-diphenyl-5-{4-[(E)-(pyridin-3-ylMethylidene)aMino]piperazin-1-yl}pentanenitrile;PF-o6341724;(E)-2,2-diphenyl-5-(4-((pyridin-3-ylMethylene)aMino)piperazin-1-yl)pentanenitrile
|
C27H29N5 |
423.55266 | |
|
Gadobutrol
|
138071-82-6 |
钆布醇
|
|
C18H31N4O9.Gd |
604.712 | 1308068-626-2 |
|
Tenofovir disoproxil fumarate
|
202138-50-9 |
富马酸替诺福韦酯
|
富马酸替诺福韦双索酯;替诺福韦酯富马酸;CS-112;CS-138;泰诺福韦酯;替诺福韦;替诺福韦酯富马酸盐;富马酸替诺福韦酯;泰诺福韦脂;富马酸替诺福韦二吡呋脂;替诺福韦酯延胡索酸盐
|
C19H30N5O10P.C4H4O4 |
635.51 | |
|
Rosuvastatin
|
287714-41-4 |
罗伐他汀
|
瑞舒伐他汀;罗苏伐他汀游离酸;R-2: TERT-BUTYL-(+)7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-METHYLSULFONYLAMINO)PYRIMIDINE-5-YL]-(3R,5S)-DIOXANE-(E)-6-HEPTENATE;CS-111;瑞舒伐他汀杂质21;瑞舒伐他汀杂质 7;ROSUVASTATIN (ZD 4522);罗素他汀;舒伐他汀
|
C22H28FN3O6S |
481.5422 | 689-191-5 |
|
Rotigotine
|
99755-59-6 |
罗替戈汀
|
罗替戈汀碱;罗替戈汀 100MG;CS-110;(S)-5,6,7,8-四氢-6-(丙基(2-(2-噻吩基)乙基)氨基)-1-萘酚;罗替戈汀;ROTIGOTINE(S构型);罗替戈汀杂质;罗替哥汀杂质
|
C19H25NOS |
315.4729 | 619-458-3 |
|
Vilazodone
|
163521-12-8 |
维拉佐酮
|
维拉唑酮;维拉佐酮(游离碱);维拉佐酮;CS-108;盐酸维拉佐酮;维拉佐酮盐酸盐;盐酸维拉佐酮C10;维拉唑酮杂质;VIIBRYD;5-(4-[4-(5-CYANO-1H-INDOL-3-YL)BUTYL]PIPERAZIN-1-YL)BENZOFURAN-3-CARBOXAMIDE
|
C26H27N5O2 |
477.993 | 1308068-626-2 |
|
abacavir
|
136470-78-5 |
阿巴卡韦
|
阿巴卡韦;阿波卡伟;阿巴卡韦;阿巴卡韦D4;(1S,4R)-4-[2-氨基-6-(环丙氨基)-9H-嘌呤-9-基]-2-环戊烯-1-甲醇;阿巴卡维;阿巴卡韦API;(1S,4R)-4-[2-氨基-6-(环丙胺基)-9H-嘌呤-9-基]-2-环戊烯-2-甲醇
|
C14H18N6O |
286.34 | 620-487-9 |
|
BRL 52537 HYDROChloride
|
130497-33-5 |
2-(3,4-二氯苯基)-1-(2-(吡咯烷-1-基甲基)哌啶-1-基)乙酮盐酸盐
|
2-(3,4-二氯苯基)-1-(2-(吡咯烷-1-甲基)哌啶-1-基)乙酮盐酸盐;2-(3,4-二氯苯基)-1-(2-(吡咯烷-1-基甲基)哌啶-1-基)乙酮盐酸盐;1-[(3,4-二氯苯基)乙酰基]-2-(1-吡咯烷基甲基)哌啶;CS-103
|
C18H25Cl3N2O |
391.76 | |
|
Fesoterodine Fumarate
|
286930-03-8 |
富马酸非索罗定
|
CS-244;富马酸非索罗定;弗斯特罗定富马酸;富马酸弗斯特罗定;非索罗定;(R)-富马酸非索罗定;CS-102;富马酸佛索特定
|
C26H37NO3.C4H4O4 |
527.64904 | 639-689-3 |
|
(4S,4aS,5aR,12aS)-9-AMino-4,7-bis(diMethylaMino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxaMide hydrochloride
|
149934-21-4 |
9-氨基米诺环素硫酸盐
|
9-氨基米诺环素硫酸盐;9-氨基米诺环素;9-氨基米诺环素盐酸盐;9-氨基米诺环素盐酸盐(替加环素中间体);9-氨基米诺环素盐酸盐,构型异构体<1.2%;(4S,4AS,5AR,12AS)-9-氨基-4,7-双(二甲基氨基)-3,10,12,12A-四羟基-1,11-二氧代-1,4,4A,5,5A,6,11,12A-八氢四C烯-2-甲酰胺盐酸盐;CS-98;替加环素中间体-9-氨基米诺环素硫酸盐
|
C23H28N4O7.ClH |
508.956 | 604-710-7 |
|
Vandetanib
|
443913-73-3 |
凡德他尼
|
范得他尼;ZD6474;ZD-6474;ZD 6474;凡他尼布;凡德它尼;凡德他尼及中间体;ZD6474;ZACTIMA;4-(4-溴-2-氟苯胺基)-6-甲氧基-7-[(1-甲基哌啶-4-基)甲氧基]喹唑啉
|
C22H24BrFN4O2 |
475.35 | 669-841-4 |
|
Afatinib
|
439081-18-2 |
阿法替尼(BIBW 2992)
|
阿法替尼2992;马来酸阿法替尼;阿法替尼;吉泰瑞;马磺酸阿法替尼片;N-[4-[(3-氯-4-氟苯基)氨基]-7-[[(3S)-四氢-3-呋喃]氧基]-6-喹唑啉]-4-(二甲基氨基)-2-丁酰胺;BIBW2992双马来酸盐 阿法替尼(BIBW 2992);阿法替尼游离碱;阿法替尼(顺反异构体混合物)
|
C24H25ClFN5O3 |
485.944 | 1308068-626-2 |
|
TG101209
|
936091-14-4 |
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺
|
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺;TG101209;TG 101209;TG-101209;CS-94
|
C26H35N7O2S |
509.67 | |
|
Ki16425
|
355025-24-0 |
KI16425
|
3-[[[4-[4-[[[1-(2-氯苯基)乙氧基]羰基]氨基]-3-甲基-5-异恶唑基]苯基]甲基]硫基]丙酸;竞争性可逆LPA拮抗剂
|
C23H23ClN2O5S |
474.963 |







